In a recent report to the Board, the CEO of Pacific Biometrics (PBI), Ron Helm, reported a second trend driving growth is the fast turnaround work the company performs developing assays for a growing scope of biomarkers, which favors “smaller labs, like PBI, that are nimble and flexible, and plays into our biomarker development strength.” Read more »
At BIO-Europe 2009, Compendia Bioscience is searching for 10 to 20 potential partners for the risk-sharing program to identify a precisely targeted patient population for a partner’s innovative cancer therapeutic, in exchange for future milestone and/or royalty payments for the successful drug. Read more »
“Success in biotechnology is tightly linked to achieving milestones critical to funding, and the second concern is protection of intellectual property,” said Detlef Behrens of Piramal Healthcare. “We have a long and deep track record both formulation and for IP protection,” he said, “It is something I look forward to discussing with potential partners at BIO-Europe in Vienna.” Read more »
With a platform to design and develop covalent drugs that have the depth and breadth to treat viral infections, cancers and autoimmune diseases, Avila Therapeutics in just three years has attracted USD 51 million in financing, and in July announced an option agreement with Novartis valued at USD 200 million in upfront payments and milestones. Read more »
“We are a truly independent solution provider,” CEO Mads Laustsen of CMC Biologics told partneringNEWS™. “We do not develop and manufacture our own biologics, nor have we entered into risk-sharing ventures. This way we can commit our full attention to our customers and take on their challenges with a high level of science, dedication and expertise to deliver a carefully customized solution.” Read more »
Michael Tansey and Grahaem Brown have combined their considerable experience and expertise in a start-up company aptly named Competitive Drug Development International (CDDI) which makes its debut at BIO-Europe in Vienna. Read more »
In what has proven to be a turbulent period for the biotech industry since Merck Serono launched its corporate venture fund in March, one deal has been announced, and Bulthuis hinted he may have news to discuss at BIO-Europe 2009 when he participates in the panel discussion “Funding Early Stage Programs in Difficult Times.”
Read more »
In July, 2009, Avila and Novartis entered into an option agreement on Avila’s advancement of a novel covalent drug program that included upfront and milestones payments to Avila, as well as an equity investment.
A rare opportunity to examine the details of a landmark deal by questioning partners on both sides of the negotiating table presents itself at BIO-Europe 2009 during a panel discussion Monday, November 2 at 1:00 pm. Read more »
Newsletter